Offspring Biosciences
A tissue- and cell-focused contract research organisation (est. 2012) providing tissue-based analytical services to support therapeutic antibody development and translational research. Services include target validation, tissue-based hit/lead screening, multiplexed histopathology, quantitative image analysis using AI, biospecimen acquisition, autoradiography, and assay optimization to generate regulatory‑grade, physiologically relevant data for pharma and biotech customers.
Industries
Nr. of Employees
small (1-50)
Offspring Biosciences
Södertälje, Vasternorrlands Lan, Sweden, Europe
Services
Characterize target expression, regulation and correlations with disease biomarkers in human and preclinical tissues to support early go/no-go decisions.
Rapid tissue-based screening of dozens of candidate antibodies on focused human tissue sets using standardized IHC protocols to accelerate lead selection.
Iterative tissue-based characterization of top candidates on comprehensive tissue panels to guide engineering for affinity, specificity and epitope accessibility.
Tissue cross-reactivity screening, species cross-reactivity, and demonstration of target engagement following in vivo administration to support IND-enabling studies.
Characterization of antibody binding and biomarker expression in larger patient cohorts and support for development of mechanism and efficacy biomarker assays for patient stratification.
Sourcing of ethically approved human biospecimens (fresh, frozen, FFPE, TMAs, blood, biofluids) with clinical metadata and custom inclusion/exclusion criteria.
Characterize target expression, regulation and correlations with disease biomarkers in human and preclinical tissues to support early go/no-go decisions.
Rapid tissue-based screening of dozens of candidate antibodies on focused human tissue sets using standardized IHC protocols to accelerate lead selection.
Iterative tissue-based characterization of top candidates on comprehensive tissue panels to guide engineering for affinity, specificity and epitope accessibility.
Tissue cross-reactivity screening, species cross-reactivity, and demonstration of target engagement following in vivo administration to support IND-enabling studies.
Characterization of antibody binding and biomarker expression in larger patient cohorts and support for development of mechanism and efficacy biomarker assays for patient stratification.
Sourcing of ethically approved human biospecimens (fresh, frozen, FFPE, TMAs, blood, biofluids) with clinical metadata and custom inclusion/exclusion criteria.
Expertise Areas
- Therapeutic antibody profiling and target validation
- Histopathology and molecular pathology
- Multiplexed biomarker discovery and validation
- Spatial biology and tumor microenvironment analysis
Key Technologies
- Immunohistochemistry (IHC)
- Multiplex immunofluorescence / immunohistochemistry
- In situ hybridization (branched-DNA ISH)
- In situ proximity ligation assay (isPLA)
News & Updates
Company leadership transition announcing Åsa Johansson as CEO.
Announcement of company contribution to PET ligand development for non‑Alzheimer tauopathies.
Overview post describing the company's support services for preclinical and clinical drug development.
Company leadership transition announcing Åsa Johansson as CEO.
Announcement of company contribution to PET ligand development for non‑Alzheimer tauopathies.
Overview post describing the company's support services for preclinical and clinical drug development.